147 related articles for article (PubMed ID: 28830135)
1. Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant Pancreatobiliary Disease.
Kim MS; Jeon TJ; Park JY; Choi J; Shin WC; Park SE; Seo JY; Kim YM
Korean J Gastroenterol; 2017 Aug; 70(2):96-102. PubMed ID: 28830135
[TBL] [Abstract][Full Text] [Related]
2. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
3. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
4. Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.
La Greca G; Sofia M; Lombardo R; Latteri S; Ricotta A; Puleo S; Russello D
World J Gastroenterol; 2012 Aug; 18(31):4150-5. PubMed ID: 22919247
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of neutrophil gelatinase-associated lipocalin in bile from patients with malignant pancreatobiliary disease.
Zabron AA; Horneffer-van der Sluis VM; Wadsworth CA; Laird F; Gierula M; Thillainayagam AV; Vlavianos P; Westaby D; Taylor-Robinson SD; Edwards RJ; Khan SA
Am J Gastroenterol; 2011 Sep; 106(9):1711-7. PubMed ID: 21670771
[TBL] [Abstract][Full Text] [Related]
6. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
Ng WW; Tong KJ; Tam TN; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
[TBL] [Abstract][Full Text] [Related]
7. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
8. Dynamic change of serum CA19-9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas.
Zhao B; Cheng Q; Cao H; Zhou X; Li T; Dong L; Wang W
BMC Cancer; 2021 May; 21(1):517. PubMed ID: 33962560
[TBL] [Abstract][Full Text] [Related]
9. Can red cell distribution width help to discriminate benign from malignant biliary obstruction? A retrospective single center analysis.
Beyazit Y; Kekilli M; Ibis M; Kurt M; Sayilir A; Onal IK; Purnak T; Oztas E; Tas A; Yesil Y; Arhan M
Hepatogastroenterology; 2012; 59(117):1469-73. PubMed ID: 22683963
[TBL] [Abstract][Full Text] [Related]
10. Effect of percutaneous biliary drainage on serum levels of tumor markers in patients with obstructive jaundice.
Koroglu M; Koroglu BK; Akhan O; Coskun HS; Yildizz H; Yesildag A; Oyar O
Hepatogastroenterology; 2006; 53(70):491-6. PubMed ID: 16995447
[TBL] [Abstract][Full Text] [Related]
11. Bilirubin levels predict malignancy in patients with obstructive jaundice.
Garcea G; Ngu W; Neal CP; Dennison AR; Berry DP
HPB (Oxford); 2011 Jun; 13(6):426-30. PubMed ID: 21609376
[TBL] [Abstract][Full Text] [Related]
12. Caution in interpretation of the tumor marker CA 19.9 in patients with obstructive jaundice: illustrative case reports.
Helling TS
J Miss State Med Assoc; 2013 Apr; 54(4):96-9. PubMed ID: 23767270
[TBL] [Abstract][Full Text] [Related]
13. Endoscopic cytology in biliary strictures. Personal experience.
Geraci G; Pisello F; Arnone E; Modica G; Sciumè C
G Chir; 2008 Oct; 29(10):403-6. PubMed ID: 18947461
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
[TBL] [Abstract][Full Text] [Related]
15. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of pyruvate kinase M2 in bile, serum carbohydrate antigen 19-9, and biliary brushings in diagnosing malignant biliary strictures.
Navaneethan U; Lourdusamy V; Poptic E; Hammel JP; Sanaka MR; Parsi MA
Dig Dis Sci; 2015 Apr; 60(4):903-9. PubMed ID: 25344422
[TBL] [Abstract][Full Text] [Related]
17. CA 19-9 assay in patients with extrahepatic cholestatic jaundice.
Barone D; Onetto M; Conio M; Paganuzzi M; Saccomanno S; Aste H; Pugliese V
Int J Biol Markers; 1988; 3(2):95-100. PubMed ID: 3243982
[TBL] [Abstract][Full Text] [Related]
18. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
19. Utility of Endoscopic Ultrasound-Guided Hepaticogastrostomy with Antegrade Stenting for Malignant Biliary Obstruction after Failed Endoscopic Retrograde Cholangiopancreatography.
Imai H; Takenaka M; Omoto S; Kamata K; Miyata T; Minaga K; Yamao K; Sakurai T; Nishida N; Watanabe T; Kitano M; Kudo M
Oncology; 2017; 93 Suppl 1():69-75. PubMed ID: 29258066
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic retrograde cholangiopancreatography for distal malignant biliary stricture.
Isayama H; Nakai Y; Kawakubo K; Kogure H; Hamada T; Togawa O; Sasahira N; Hirano K; Tsujino T; Koike K
Gastrointest Endosc Clin N Am; 2012 Jul; 22(3):479-90. PubMed ID: 22748244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
